Markets:

Overview

News

Currencies

International

Treasuries

Artivion, Inc. Common Stock (NY:AORT)

34.19 -2.43 (-6.64%)

Streaming Delayed Price Updated: 3:54 PM EDT, Apr 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Artivion, Inc. Common Stock

< Previous 1 2 3 4 5 Next >

1 Profitable Stock with Impressive Fundamentals and 2 That Underwhelm

March 31, 2026

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...

Via StockStory

Artivion, Intuitive Surgical, GE HealthCare, LeMaitre, and Globus Medical Shares Plummet, What You Need To Know

March 27, 2026

What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in...

Via StockStory

Topics Government Stocks

3 of Wall Street’s Favorite Stocks We Steer Clear Of

March 23, 2026

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...

Via StockStory

Artivion Inc (NYSE:AORT) Shares Drop on Q4 Revenue Miss Despite Earnings Beat ↗

February 12, 2026

Via Chartmill

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Envista, Baxter, Artivion, Dentsply Sirona, and Cigna Stocks Trade Down, What You Need To Know

March 06, 2026

What Happened? A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in employment, with the hea...

Via StockStory

Topics Economy

5 Must-Read Analyst Questions From Artivion’s Q4 Earnings Call

February 19, 2026

Artivion’s fourth quarter results were met with a negative market reaction, as revenue came in just below Wall Street’s expectations. Management attributed the quarter’s performance to robust demand...

Via StockStory

Topics Earnings

Artivion (AORT) Stock Trades Down, Here Is Why

February 13, 2026

Shares of medical device company Artivion (NYSE:AORT) fell 5.8% in the morning session after the company reported mixed fourth-quarter 2025 financial results, with revenues falling short of analyst...

Via StockStory

AORT Q4 Deep Dive: Stent Graft and On-X Growth Offset By Tissue Flatness, Guidance Highlights Pipeline

February 13, 2026

Medical device company Artivion (NYSE:AORT) missed Wall Street’s revenue expectations in Q4 CY2025, but sales rose 19.2% year on year to $116 million. On the other hand, the company’s full-year revenue...

Via StockStory

Artivion (AORT) Q4 2025 Earnings Call Transcript ↗

February 12, 2026

Artivion (AORT) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Artivion (NYSE:AORT) Misses Q4 CY2025 Sales Expectations

February 12, 2026

Medical device company Artivion (NYSE:AORT) fell short of the market’s revenue expectations in Q4 CY2025, but sales rose 19.2% year on year to $116 million. On the other hand, the company’s full-year...

Via StockStory

What To Expect From Artivion’s (AORT) Q4 Earnings

February 10, 2026

Medical device company Artivion (NYSE:AORT) will be reporting results this Thursday afternoon. Here’s what to look for.

Via StockStory

Topics Artificial Intelligence World Trade

2 Stocks Under $50 to Research Further and 1 We Avoid

January 26, 2026

Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and...

Via StockStory

1 Profitable Stock with Exciting Potential and 2 Facing Headwinds

January 12, 2026

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

Via StockStory

1 Healthcare Stock on Our Watchlist and 2 We Ignore

January 04, 2026

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only realized strong financial performance but also...

Via StockStory

Topics Stocks

3 Reasons to Sell AORT and 1 Stock to Buy Instead

January 01, 2026

What a time it’s been for Artivion. In the past six months alone, the company’s stock price has increased by a massive 47.8%, reaching $45.61 per share. This was partly thanks to its solid quarterly...

Via StockStory

Topics Supply Chain

1 Safe-and-Steady Stock on Our Watchlist and 2 We Avoid

December 28, 2025

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

Via StockStory

3 Cash-Producing Stocks with Questionable Fundamentals

December 17, 2025

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...

Via StockStory

Topics Retirement

Artivion (AORT) Stock Is Up, What You Need To Know

December 17, 2025

Shares of medical device company Artivion (NYSE:AORT) jumped 4.6% in the afternoon session after analyst firm Canaccord Genuity reaffirmed its Buy rating and $51.00 price target, pointing to the...

Via StockStory

Topics Artificial Intelligence Economy

3 Russell 2000 Stocks That Concern Us

December 07, 2025

The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher...

Via StockStory

Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q3 Teardown: Artivion (NYSE:AORT) Vs The Rest

November 25, 2025

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q3. Today, we are looking at medical devices & supplies - cardiology,...

Via StockStory

Oscar Health and Artivion Shares Are Soaring, What You Need To Know

November 21, 2025

A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated...

Via StockStory

Topics Artificial Intelligence Economy Initial Public Offering

5 Must-Read Analyst Questions From Artivion’s Q3 Earnings Call

November 13, 2025

Artivion delivered a Q3 marked by strong revenue growth and a positive market response, as ongoing adoption of its stent grafts and On-X heart valves fueled performance. Management highlighted...

Via StockStory

Topics Earnings

3 Small-Cap Stocks We Approach with Caution

November 12, 2025

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside...

Via StockStory

Gilead Sciences, Moderna, Artivion, Tenet Healthcare, and Charles River Laboratories Stocks Trade Up, What You Need To Know

November 11, 2025

A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid...

Via StockStory

Topics Artificial Intelligence Stocks

November 10, 2025

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other...

Via StockStory

AORT Q3 Deep Dive: AMDS and On-X Outperform, Pipeline and Reimbursement Bolster Outlook

November 07, 2025

Medical device company Artivion (NYSE:AORT) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 18.4% year on year to $113.4 million. The company’s full-year revenue...

Via StockStory

Artivion Stock: A Deep Dive Into Analyst Perspectives (6 Ratings) ↗

November 07, 2025

Via Benzinga

Artivion Inc (NYSE:AORT) Reports Q3 2025 Revenue Beat and Steady Earnings ↗

November 06, 2025

Artivion (AORT) Q3 2025 revenue beat expectations with 18.4% YoY growth, while EPS aligned with estimates. The medical device firm shows strong momentum.

Via Chartmill

Artivion’s (NYSE:AORT) Q3 Sales Top Estimates

November 06, 2025

Medical device company Artivion (NYSE:AORT) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 18.4% year on year to $113.4 million. The company’s full-year revenue guidance of $442...

Via StockStory

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.